Avenir® Cemented Hip Stem - PMCF

N/AActive Not RecruitingNCT03396224

Zimmer Biomet100 enrolled

Overview

The objective of this post-market clinical follow-up study is to confirm the safety and performance of the Avenir® Cemented Hip stem when used in primary total hip arthroplasty.

This is a multicenter, prospective, non-controlled post-market clinical follow-up study to fulfill the post market surveillance obligations according to Medical Device Directive and MEDDEV 2.12-2. The objectives of this study are to confirm the safety and performance of the Avenir Cemented Hip Stem when used in primary total hip arthroplasty at 6 weeks to 6 months, 1, 2, 3, 5, 7 and 10 years post-operatively. The Avenir Cemented Hip Stem is a straight double-tapered stem offering 9 standard and 9 lateralized versions, the same as the uncemented version, the Avenir-Mueller Stem. Safety will be evaluated by monitoring the frequency and incidence of adverse events and through radiographic review. Performance will be based on the implant survival, overall pain and functional performances, subject quality-of-life and radiographic parameters of study subjects who received the Avenir® Cemented Hip stem. Implant survival will be based on removal or intended removal of the device. A total of 130 patients will be enrolled into the study at up to 4 sites.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Primary Osteoarthritis Post-Traumatic Osteoarthritis of Hip Femoral Neck Fractures Femoral Head Necrosis Sequelae From Previous Hip Surgery Osteotomies Congenital Hip Dysplasia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient is 18 years of age minimum. * Patient is suffering from severe hip pain and disability requiring primary unilateral or bilateral total hip arthroplasty based on physical exam and medical history. * Patient is willing and able to cooperate in the required post-operative therapy. * Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent. Exclusion Criteria: * Patient is unwilling or unable to give consent, or to comply with the follow-up program. * Acute, chronic, local, or systemic infections. * Severe muscular, neural, or vascular diseases that endanger the limbs involved. * Lack of bony structures proximal or distal to the joint, so that good anchorage of the implant is unlikely or impossible. * Total or partial absence of the muscular or ligamentous apparatus. * Any concomitant diseases that can jeopardize the functioning and the success of the implant. * Allergy to the implanted material, especially to metal (e.g., stainless steel). * Local bone tumors and/or cysts. * Pregnancy * Skeletal immaturity * Patients who have any condition that would in the judgment of the Investigator place the patient at undue risk or interfere with the study. Any patient who is institutionalized, a known drug abuser or alcoholic or anyone who cannot understand what is required of them. * Patients with plans to relocate during the study follow-up period. * For patients biologically younger than 60 years with joint disease, a different reconstruction operation (e.g., osteotomy) or arthrodesis may be indicated.

Locations (3)

Cliniques Universitaires St-Luc UCL

Woluwe-Saint-Lambert, Brussels Capital, Belgium

Hôpital Gabriel Montpied - Service de chirurgie Orthopédique

Clermont-Ferrand, Auvergne-Rhône-Alpes, France

Hopital Lapeyronie - Service Orthopédie

Montpellier, Occitanie, France

Outcomes

Primary Outcomes

Implant survival based on removal or intended removal of the device and determined using the Kaplan-Meier method

Time frame: 10 years

Secondary Outcomes

The results of the hip surgery will be determined by the Harris Hip Score

The Harris Hip Score is a questionnaire filled by the surgeon with the patient who received a hip implant. The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities (stair use, using public transportation, sitting, and managing shoes and socks) and gait (limp, support needed, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. There are 10 items. The score has a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).

Time frame: 10 years

The patient's quality-of-life will be determined by the EQ-5D score

EQ-5D is a standardized instrument for measuring health status. It is made up for two components. The description part: health status is measured in five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself. Usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have. In anxiety/depression dimension, it asks how anxious or depressed they are. Visual analogue scale: The patient marks his health status on the day of the interview on a 20 cm vertical scale with end points of 0 and 100. The bottom rate (0) corresponds to " the worst health you can imagine", and the highest rate (100) corresponds to "the best health you can imagine".

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.